Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-453 in Biomarker-Selected Relapsed/Refractory Multiple Myeloma
NCT05308654Phase 1Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- May 2022
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of surzetoclax in multiple myeloma (MM) (5 arms), sponsored by AbbVie Inc. Primary endpoint: Overall Response Rate at 12 months. Started May 2022; status: active, not recruiting.
02
Drugs
surzetoclax
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05308654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05308654.